Abstract:1297 Objectives The standard uptake value (SUV) of 18F-FDG PET/CT is important in the diagnosis and treatment response evaluation of lung cancer. The aim of the present study is to investigate the clinical value of SUV of 99mTc-3PRGD2 SPECT/CT in lung cancer diagnosis. Methods Twenty-four patients with pathologically approved lung cancer (21 non-small cell lung cancer and 3 small cell lung cancer),4 patients with benign diseases (3 pulmonary consolidation and 1 adenoma), and 6 healthy volunteers were enrolled in the study. All subjects were injected with 629.0-921.3 MBq of 99mTc-3PRGD2 (mean ± SD, 759.3 ± 80.1 MBq), and a SPECT/CT (Discovery NM/CT 670, GE Healthcare) was performed 30 minutes later. The images were analyzed using Q.Metrix (GE Healthcare) after OSEM reconstruction with resolution recovery technology, scatter correction and Xray CT based attenuation correction. The mean SUV (SUVmean) and the maximum SUV (SUVmax) of the superior, middle, and inferior mediastinum and the right lower lobe of the liver in healthy volunteers, as well as the corresponding values of the primary lesions in the patients, were measured with a 3 cm-diameter volume of interest (VOI). The longest diameters of the primary lesions in CT images of the patients were measured as well. Results The median age of the lung cancer patients, benign disease patients and healthy volunteers was 60.5 (43-76) years old, 62.0 (52-76) years old and 56.0 (44-64) respectively. Fourteen of the 24 lung cancer patients (58.3%), 2 of the 4 benign disease patients (50%) and 3 of the 6 healthy volunteers (50%) were male. The mean value of the SUVmean and the SUVmax of the superior, middle, and inferior mediastinum were 0.64 ± 0.27 g/ml and 1.06 ± 0.41 g/ml. The SUVmean and the SUVmax of the right lower lobe of the liver in healthy volunteers were 1.85 ± 0.72 g/ml and 2.35 ± 0.92 g/ml. The longest diameter of the primary lesion in CT images in the 24 lung cancer patients was 3.68 ± 2.02 cm; the corresponding SUVmean and SUVmax values were 1.67 ± 1.04 g/ml and 3.68 ± 2.12 g/ml. In the 4 benign lesions, the longest diameter in CT images was 2.60 ± 0.45 cm, and the SUVmean and SUVmax were 0.64 ± 0.27 g/ml and 0.96 ± 0.36 g/ml, respectively. The diagnostic sensitivity, specificity and accuracy of SUVmean and SUVmax of 99mTc-3PRGD2 in lung carcinoma verses the mean + 2SD of mediastinum were 0.67, 1.00, 0.71 and 0.67, 1.00, 0.71, respectively. Conclusions (1) The mean + 2SD of the SUV mean and SUVmax of mediastinum seems a valid threshold for 99mTc-3PRGD2 SPECT/CT in lung carcinoma diagnosis; (2) SUV of 99mTc-3PRGD2 SPECT/CT, as an indicator of lung cancer, is in good compliance and accordance with pathological diagnosis. The SUV of 99mTc-3PRGD2 SPECT/CT is a promising tool in the diagnosis and differential diagnosis of lung cancer. RESEARCH SUPPORT: This work was financially supported, in part, by the National Natural Science Foundation of China (NSFC) projects (Grant No.81071188, 81571713 and 81171369) and Beijing Municipal Science & Technology Commission (Grant No.Z151100003915133)

Comparison of 99Mtc-3Prgd2 Integrin Receptor Imaging with 99Mtc-Mdp Bone Scan in Diagnosis of Bone Metastasis in Patients with Lung Cancer: a Multicenter Study.

99Mtc-3Prgd2 for Integrin Receptor Imaging of Lung Cancer: A Multicenter Study

Integrin Receptor Imaging of Breast Cancer Using 99Mtc-3Prgd2 SPECT/CT: Compared with 18F-FDG PET/CT

Integrin Receptor Imaging 99Mtc-3Prgd2 SPECT/CT in Diagnosis and Lymph Node Staging of Non-Small Cell Lung Cancer

Integrin Imaging with 99Mtc-3Prgd2 SPECT/CT Shows High Specificity in the Diagnosis of Lymph Node Metastasis from Non-Small Cell Lung Cancer.

An Exploratory Study on 99Mtc-Rgd-bbn Peptide Scintimammography in the Assessment of Breast Malignant Lesions Compared to 99Mtc-3P4-rgd2.

Evaluation of Standard Uptake Value of 99Mtc-3Prgd2 Spect/Ct in Lung Cancer Diagnosis

Comparison of the Value of ~(18)F-FDG PET and ~(99)Tc~m-MDP Bone Scan in the Detection of Bone Metastases

Comparison of Diagnostic and Prognostic Value of 99Mtc-Mdp-planar Bone Scintigraphy, 131I-Spect/ct And18f-Fdg-Pet/Ct for Detection of Bone Metastases from Differentiated Thyroid Cancer

68Ga-P15-041, A Novel Bone Imaging Agent for Diagnosis of Bone Metastases

Prospective comparison of 68Ga-DOTA-ibandronate and bone scans for detecting bone metastases in breast cancer

Comparative Study of ~(18)F-FDG Coincidence Imaging and ~(99) Tc~m-MDP Bone Scan in Diagnosing Lung Cancer with Bone Metastases

The comparative study of 18 F - FDG PET / CT and 99 Tcm - MDP bone scintigraphy in de-tecting bone metastasis

Head-to-head comparison of 99mTc-PSMA and 99mTc-MDP SPECT/CT in diagnosing prostate cancer bone metastasis: a prospective, comparative imaging trial

Comparison of 68Ga-PSMA-617 PET/CT and 99Tcm-MDP bone scintigraphy for bone metastases in prostate cancer

Comparison of the diagnostic and prognostic values of 99mTc-MDP-planar bone scintigraphy, 131I-SPECT/CT and 18F-FDG-PET/CT for the detection of bone metastases from differentiated thyroid cancer.

99Mtc-3P4-rgd2 Scintimammography in the Assessment of Breast Lesions: Comparative Study with 99Mtc-Mibi

Evaluation of Tc-99m-3prgd2 Integrin Receptor Imaging in the Differential Diagnosis of Breast Lesions and Comparison with Mammography

Prostate-specific membrane antigen PET versus [99mTc]Tc-MDP bone scan for diagnosing bone metastasis in prostate cancer: a head-to-head comparative meta-analysis

The Efficacy of 18F-FDG PET/CT, 99Tcm-Mdp Bone Scintigraphy, and Combination of the Two Techniques for Detecting Malignant Bone Metastasis

Evaluation of 99Tcm-3Prgd2 Integrin Receptor Imaging in Qualitative Diagnosis of Breast Cancer and Its Comparison with Mammography